3C Patch for treating diabetic foot ulcers (MTG66)Product type:GuidanceProgramme:Medical technologies guidancePublished: 7 March 2022
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (IPG257)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 April 2008
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 September 2008
Brolucizumab for treating diabetic macular oedema (TA820)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2022
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2016
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2008
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 23 November 2016Published: 26 June 2013
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 November 2016
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)Product type:GuidanceProgramme:NICE guidelineLast updated: 16 December 2020Published: 25 February 2015
Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)Product type:GuidanceProgramme:NICE guidelineLast updated: 11 May 2023Published: 1 August 2015
Diabetic foot problems: prevention and management (NG19)Product type:GuidanceProgramme:NICE guidelineLast updated: 11 October 2019Published: 26 August 2015
Diabetic retinopathy: management and monitoring (NG242)Product type:GuidanceProgramme:NICE guidelinePublished: 13 August 2024
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) (TA1006)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 September 2024
Empagliflozin in combination therapy for treating type 2 diabetes (TA336)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 March 2015
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 16 May 2024
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2019
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2019
Faricimab for treating diabetic macular oedema (TA799)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2023
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2023
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (IPG518)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2015
Neuropad for detecting preclinical diabetic peripheral neuropathy (MTG38)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 21 September 2022Published: 10 September 2018
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2023Published: 27 February 2013
Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 June 2020
Sotagliflozin with insulin for treating type 1 diabetes (TA622)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 February 2020
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 25 March 2019Published: 25 March 2014
Tirzepatide for treating type 2 diabetes (TA924)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Type 1 diabetes in adults: diagnosis and management (NG17)Product type:GuidanceProgramme:NICE guidelineLast updated: 17 August 2022Published: 26 August 2015
Type 2 diabetes in adults: management (NG28)Product type:GuidanceProgramme:NICE guidelineLast updated: 29 June 2022Published: 2 December 2015
Type 2 diabetes: prevention in people at high risk (PH38)Product type:GuidanceProgramme:Public health guidelineLast updated: 15 September 2017Published: 12 July 2012
Type 2 diabetes prevention: population and community-level interventions (PH35)Product type:GuidanceProgramme:Public health guidelinePublished: 10 May 2011
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 1 March 2015Published: 31 December 2014